GlassScriptPhysician profile
Winder N Vasquez
NPI 1265460026
$3,505.36
in general payments reported to CMS, 2019-2025
29 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $355 · 2021: $608 · 2022: $289 · 2023: $482 · 2024: $526 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.89 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $579.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $530.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $518.69 | 2019-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.22 | 2019-2025 | Jardiance, Jascayd |
| Insmed, INC. | $170.01 | 2024-2025 | Brinsupri, Arikayce |
| Corcept Therapeutics | $140.13 | 2022-2025 | Korlym |
| Abbvie INC. | $130.71 | 2021 | |
| Amgen INC. | $127.16 | 2022-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $113.50 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $94.99 | 2023 | |
| Merck Sharp & Dohme LLC | $71.86 | 2021-2024 | Keytruda |
| Amarin Pharma, INC. | $64.44 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.09 | 2021-2024 | |
| Electromed, INC. | $52.14 | 2024-2025 | Smartvest |
| Sumitomo Pharma America, INC. | $49.98 | 2025 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.97 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $43.75 | 2020-2021 | |
| Pfizer INC. | $31.60 | 2020-2021 | |
| Baxter Healthcare | $30.16 | 2023 | Hillrom - Life 2000 Ventilation System |
| Phathom Pharmaceuticals, INC. | $26.04 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $25.65 | 2024 | Austedo Xr |
| Shionogi INC | $20.97 | 2022 | |
| Eisai INC. | $20.01 | 2021 | |
| Allergan, INC. | $16.30 | 2019 | |
| Philips North America LLC | $16.30 | 2020 | |
| Evoke Pharma, INC. | $16.19 | 2020 | |
| Opko Pharmaceuticals, LLC | $16.07 | 2024 | Rayaldee |
| Sonex Health, INC. | $14.71 | 2024 | Sx-One Microknife |
| Advanced Respiratory, INC | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winder Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.